Last reviewed · How we verify
Proactive TDM-based dosing of guselkumab — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab) — University Hospital, Ghent.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Proactive TDM-based dosing of guselkumab TARGET | Proactive TDM-based dosing of guselkumab | University Hospital, Ghent | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Proactive TDM-based dosing of guselkumab CI watch — RSS
- Proactive TDM-based dosing of guselkumab CI watch — Atom
- Proactive TDM-based dosing of guselkumab CI watch — JSON
- Proactive TDM-based dosing of guselkumab alone — RSS
Cite this brief
Drug Landscape (2026). Proactive TDM-based dosing of guselkumab — Competitive Intelligence Brief. https://druglandscape.com/ci/proactive-tdm-based-dosing-of-guselkumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab